MAP2K7 and acute lymphoblastic leukemia: Of note, two t(17;19)‐ALL cell lines and four t(1;19)‐ALL cell lines with the KRAS mutation were relatively more sensitive to selumetinib, a MEK inhibitor, than two t(17;19)‐ALL cell lines and 12 t(1;19)‐ALL cell lines without the mutation.